Although ligelizumab binds IgE with an approximately 4-fold higher affinity than that of UB-221 on SPR (Figure 6), both mAbs bind mIgE on B cells (Figure 5A), and neutralize free IgE on ELISA (Supplemental Figure 7) and serum free IgE in sera of patients with AD (Figure 7), with equal strength. Here, IGHE is linked to Alzheimer disease.